Regeneron Pharmaceuticals, Inc. (REGN)

REGN's stock fell 8.71% following The Food and Drug Administration (FDA)'s rejection of an 8-milligram-dose version of Regeneron Pharmaceuticals' eye drug Eylea.

https://www.investors.com/news/technology/regn-stock-crumbles-after-the-fda-rejects-its-next-possible-blockbuster/?src=A00220